Liposomes techniques of aerosolization for the treatment of obstructive, restrictive and infectious pulmonary diseases: a review
DOI:
https://doi.org/10.33448/rsd-v12i1.36950Keywords:
Liposomes; Dry powder inhalers; Nanotechnology; Lung diseases.Abstract
The current treatment of lung diseases, such as tuberculosis, chronic obstructive pulmonary disease (COPD), asthma, cancer and SARS-CoV-2, presents problems related to drug administration. Thus, nanotechnology, an innovative method that stands out in recent years, especially in nanomedicine, due to the development of materials on the nanometer scale (1-1000 nm). Among the various nanosystems, liposomes for their physicochemical properties, which make them a technology of interest to encapsulate hydrophilic or hydrophobic drugs, in addition to enabling controlled drug release. These techniques employed using an inhalation route have been considered as an alternative to deliver drugs encapsulated in site-specific liposomes. For this purpose, the literature describes several liposome aerosolization techniques in order to optimize an aerosolization system. The objective of this research was to carry out a bibliographic survey of the use of liposomes in the treatment of lung diseases as well as patents related to liposomes in aerosol dosage form. According to articles searched in Science Direct, Springer Nature, National Library of Medicine (PubMed) and Scientific Electronic Library Online (SCIELO) databases on the most used techniques such as Spray Drying, Spray Freeze Drying and Freeze Drying, specifically spray-drying is described in the literature as the solution base as the one that favors obtaining vesicles with low density, good fluidity and good dispersibility. In short, it was found that, linked to the use of spray-drying and nanotechnology, the inhalation route is a promising route for the administration of drugs aimed at the of lung diseases.
References
Akgün, K. M., Crothers, K., & Pisani, M. (2012). Epidemiology and management of common pulmonary diseases in older persons. Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences, 67(3), 276-291.
Alavi, M., Karimi, N., & Safaei, M. (2017). Application of various types of liposomes in drug delivery systems. Advanced pharmaceutical bulletin, 7(1), 3.
Alipoor, S. D., Adcock, I. M., Garssen, J., Mortaz, E., Varahram, M., Mirsaeidi, M., & Velayati, A. (2016). The roles of miRNAs as potential biomarkers in lung diseases. European journal of pharmacology, 791, 395-404.
Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: from concept to clinical applications. Advanced drug delivery reviews, 65(1), 36-48.
Anderson, C. F., Grimmett, M. E., Domalewski, C. J., & Cui, H. (2020). Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 12(1), e1586.
Anjali, P. S., & Mahto, S. K. (2016). Revisiting pulmonary diseases using microfluidic technology. Int J Biosen Bioelectron, 1(1), 00001.
Azarmi, S., Roa, W. H., & Löbenberg, R. (2008). Targeted delivery of nanoparticles for the treatment of lung diseases. Advanced drug delivery reviews, 60(8), 863-875.
Barreiro, E., Wang, X., & Tang, J. (2019). COPD: preclinical models and emerging therapeutic targets. Expert Opinion on Therapeutic Targets, 23(10), 829-838.
Bassetti, M., Vena, A., Russo, A., & Peghin, M. (2020). Inhaled liposomal antimicrobial delivery in lung infections. Drugs, 80(13), 1309-1318.
Basha, R., T S, S. K., & Doble, M. (2019). Dual delivery of tuberculosis drugs via cyclodextrin conjugated curdlan nanoparticles to infected macrophages. Carbohydrate polymers, 218, 53–62.
Bathla, G., Khandelwal, G., Maller, D., Vinod, G., & Gupta, A. (2011). Manifestations of cerebral tuberculosis. Singapore Medical Association, 52(2), 124-131.
Berg, K., & Wright, J. L. (2016). The pathology of chronic obstructive pulmonary disease: progress in the 20th and 21st centuries. Archives of pathology & laboratory medicine, 140(12), 1423-1428.
Bi, R., Shao, W., Wang, Q., & Zhang, N. (2008). Spray-freeze-dried dry powder inhalation of insulin-loaded liposomes for enhanced pulmonary delivery. Journal of drug targeting, 16(9), 639-648.
Bodkhe, S., Nikam, M., Sherje, A. P., Khan, T., Suvarna, V., & Patel, K. (2020). Current insights on clinical efficacy of roflumilast for treatment of COPD, asthma and ACOS. International Immunopharmacology, 88, 106906.
Bozzuto, G., & Molinari, A. (2015). Liposomes as nanomedical devices. International journal of nanomedicine, 10, 975.
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 68(6), 394-424.
Butov, D., Feshchenko, Y., Kuzhko, M., Gumenuik, M., Yurko, K., Grygorova, A., & Butova, T. (2020). Effectiveness of intravenous isoniazid and ethambutol administration in patients with tuberculosis meningoencephalitis and HIV infection. Tuberculosis and Respiratory Diseases, 83(1), 96-103.
Calucho, M., Gartner, S., Barranco, P., Fernández-Álvarez, P., Pérez, R. G., & Tizzano, E. F. (2021). Validation of nasospheroids to assay CFTR functionality and modulator responses in cystic fibrosis. Scientific reports, 11(1), 1-11.
Carr, L. L., Jacobson, S., Lynch, D. A., Foreman, M. G., Flenaugh, E. L., Hersh, C. P., & Bowler, R. P. (2018). Features of COPD as predictors of lung cancer. Chest, 153(6), 1326-1335.
Cavalcanti, I. D. L., & Cajuba de Britto Lira Nogueira, M. (2020). Pharmaceutical nanotechnology: which products are been designed against COVID-19?. Journal of Nanoparticle Research, 22(9), 1-11.
Chennakesavulu, S., Mishra, A., Sudheer, A., Sowmya, C., Reddy, C. S., & Bhargav, E. (2018). Pulmonary delivery of liposomal dry powder inhaler formulation for effective treatment of idiopathic pulmonary fibrosis. Asian journal of pharmaceutical sciences, 13(1), 91-100.
Chiang, Y. T., Lyu, S. Y., Wen, Y. H., & Lo, C. L. (2018). Preparation and characterization of electrostatically crosslinked polymer–liposomes in anticancer therapy. International journal of molecular sciences, 19(6), 1615.
Chougule, M., Padhi, B., & Misra, A. (2007). Nano-liposomal dry powder inhaler of tacrolimus: preparation, characterization, and pulmonary pharmacokinetics. International journal of nanomedicine, 2(4), 675.
Chougule, M., Padhi, B., & Misra, A. (2008). Development of spray dried liposomal dry powder inhaler of dapsone. Aaps Pharmscitech, 9(1), 47-53.
Corlateanu, A., Covantev, S., Mathioudakis, A. G., Botnaru, V., & Siafakas, N. (2016). Prevalence and burden of comorbidities in chronic obstructive pulmonary disease. Respiratory investigation, 54(6), 387-396.
Dashraath, P., Wong, J. L. J., Lim, M. X. K., Lim, L. M., Li, S., Biswas, A., & Su, L. L. (2020). Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. American journal of obstetrics and gynecology, 222(6), 521-531.
De Sousa, V. M. L., & Carvalho, L. (2018). Heterogeneity in lung cancer. Pathobiology, 85(1-2), 96-107.
Dellaquila, A., Thomée, E. K., McMillan, A. H., & Lesher-Pérez, S. C. (2020). Lung-on-a-chip platforms for modeling disease pathogenesis. In Organ-on-a-chip (pp. 133-180). Academic Press.
Dömling, A., & Gao, L. (2020). Chemistry and Biology of SARS-CoV-2. Chem 6: 1283–1295.
Dua, K., Rapalli, V. K., Shukla, S. D., Singhvi, G., Shastri, M. D., Chellappan, D. K., & Hansbro, P. M. (2018). Multi-drug resistant Mycobacterium tuberculosis & oxidative stress complexity: Emerging need for novel drug delivery approaches. Biomedicine & Pharmacotherapy, 107, 1218-1229.
Dudoignon, E., Caméléna, F., Deniau, B., Habay, A., Coutrot, M., Ressaire, Q., & Dépret, F. (2021). Bacterial pneumonia in COVID-19 critically ill patients: a case series. Clinical Infectious Diseases, 72(5), 905-906.
Düesberg, U., Wosniok, J., Naehrlich, L., Eschenhagen, P., & Schwarz, C. (2020). Risk factors for respiratory Aspergillus fumigatus in German Cystic Fibrosis patients and impact on lung function. Scientific Reports, 10(1), 1-9.
Duffy, S. P., & Criner, G. J. (2019). Chronic obstructive pulmonary disease: evaluation and management. Medical Clinics, 103(3), 453-461.
Ehteshami-Afshar, S., FitzGerald, J. M., Doyle-Waters, M. M., & Sadatsafavi, M. (2016). The global economic burden of asthma and chronic obstructive pulmonary disease. The International Journal of Tuberculosis and Lung Disease, 20(1), 11-23.
Elibol, E. (2021). Otolaryngological symptoms in COVID-19. European Archives of Oto-Rhino-Laryngology, 278(4), 1233-1236.
El-Sayed, A., & Kamel, M. (2020). Advances in nanomedical applications: diagnostic, therapeutic, immunization, and vaccine production. Environmental Science and Pollution Research, 27(16), 19200-19213.
Estevez, H., Palacios, A., Gil, D., Anguita, J., Vallet-Regi, M., González, B., & Luque-Garcia, J. L. (2020). Antimycobacterial effect of selenium nanoparticles on mycobacterium tuberculosis. Frontiers in microbiology, 11, 800.
Fernandes, N., M. M., Araújo Machado, R. I., Bezerra, F. L., Nunes Melo, M. C., Alves, M. G. C. F., Alves Filgueira, L. G., & Rocha, H. A. O. (2017). Antibacteria, antiproliferative, and immunomodulatory activity of silver nanoparticles synthesized with fucans from the alga Dictyota mertensii. Nanomaterials, 8(1), 6.
Forum Of International Respiratory Societies (2017). The Global Impact of Respiratory Disease, Second Edition European Respiratory Society, Sheffield.
Fujiwara, M., Kawasaki, M., Hariguchi, N., Liu, Y., & Matsumoto, M. (2018). Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis. Tuberculosis, 108, 186-194.
Furin, J., Cox, H., & Pai, M. (2019). Tuberculosis. Lancet (London, England), 393(10181), 1642-1656.
Gaul, R., Ramsey, J. M., Heise, A., Cryan, S. A., & Greene, C. M. (2018). Nanotechnology approaches to pulmonary drug delivery: Targeted delivery of small molecule and gene-based therapeutics to the lung. In Design of nanostructures for versatile therapeutic applications (pp. 221-253). William Andrew Publishing.
Gavriatopoulou, M., Ntanasis-Stathopoulos, I., Korompoki, E., Fotiou, D., Migkou, M., Tzanninis, I. G., Psaltopoulou, T., Kastritis, E., Terpos, E., & Dimopoulos, M. A. (2021). Emerging treatment strategies for COVID-19 infection. Clinical and experimental medicine, 21(2), 167–179.
Geraets, L., Oomen, A. G., Krystek, P., Jacobsen, N. R., Wallin, H., Laurentie, M., Verharen, H. W., Brandon, E. F., & de Jong, W. H. (2014). Tissue distribution and elimination after oral and intravenous administration of different titanium dioxide nanoparticles in rats. Particle and fibre toxicology, 11, 30.
Global Initiative For Asthma (GINA) (2016). Pocket guide for asthma management and prevention.
Global Initiative For Chronic Obstructive Lung Disease (GOLD) (2021) . 2021 Global Strategy for Prevention, Diagnosis and Management of COPD.
Ghosh, N., Choudhury, P., Joshi, M., Bhattacharyya, P., Roychowdhury, S., Banerjee, R., & Chaudhury, K. (2021). Global metabolome profiling of exhaled breath condensates in male smokers with asthma COPD overlap and prediction of the disease. Scientific Reports, 11(1), 1-14.
Goyal, A. K., Garg, T., Bhandari, S., & Rath, G. (2017). Advancement in pulmonary drug delivery systems for treatment of tuberculosis. In Nanostructures for drug delivery (pp. 669-695). Elsevier.
Grotz, E., Tateosian, N., Amiano, N., Cagel, M., Bernabeu, E., Chiappetta, D. A., & Moretton, M. A. (2018). Nanotechnology in tuberculosis: state of the art and the challenges ahead. Pharmaceutical Research, 35(11), 1-22.
Gupta, P. V., Nirwane, A. M., Belubbi, T., & Nagarsenker, M. S. (2017). Pulmonary delivery of synergistic combination of fluoroquinolone antibiotic complemented with proteolytic enzyme: a novel antimicrobial and antibiofilm strategy. Nanomedicine: Nanotechnology, Biology and Medicine, 13(7), 2371-2384.
Higham, A., Quinn, A. M., Cançado, J. E. D., & Singh, D. (2019). The pathology of small airways disease in COPD: historical aspects and future directions. Respiratory research, 20(1), 1-11.
Hong, L., Luo, S. H., Yu, C. H., Xie, Y., Xia, M. Y., Chen, G. Y., & Peng, Q. (2019). Functional nanomaterials and their potential applications in antibacterial therapy. Pharmaceutical Nanotechnology, 7(2), 129-146.
Husebø, G. R., Nielsen, R., Hardie, J., Bakke, P. S., Lerner, L., D'Alessandro-Gabazza, C., & Eagan, T. (2019). Risk factors for lung cancer in COPD–results from the Bergen COPD cohort study. Respiratory medicine, 152, 81-88.
Ignatova, G. L., Avdeev, S. N., & Antonov, V. N. (2021). Comparative effectiveness of pneumococcal vaccination with PPV23 and PCV13 in COPD patients over a 5-year follow-up cohort study. Scientific Reports, 11(1), 1-10.
Ita, K. (2021). Coronavirus disease (COVID-19): Current status and prospects for drug and vaccine development. Archives of medical research, 52(1), 15-24.
Jackson, K., & Bahna, S. L. (2020). Hypersensitivity and adverse reactions to biologics for asthma and allergic diseases. Expert review of clinical immunology, 16(3), 311-319.
Jarych, D., Augustynowicz-Kopec, E., Iwanska, A., Parniewski, P., & Majchrzak, M. (2021). Molecular analysis of Pseudomonas aeruginosa strains isolated from cystic fibrosis patients. Scientific Reports, 11(1), 1-9.
Kadam, A. N., Najlah, M., Wan, K. W., Ahmed, W., Crean, S. J., Phoenix, D. A., & Elhissi, A. M. (2014). Stability of parenteral nanoemulsions loaded with paclitaxel: the influence of lipid phase composition, drug concentration and storage temperature. Pharmaceutical Development and Technology, 19(8), 999-1004.
Kamaly, N., Yameen, B., Wu, J., & Farokhzad, O. C. (2016). Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chemical reviews, 116(4), 2602-2663.
Kessels, S. J., Carter, D., Ellery, B., Newton, S., & Merlin, T. L. (2020). Prenatal genetic testing for cystic fibrosis: a systematic review of clinical effectiveness and an ethics review. Genetics in Medicine, 22(2), 258-267.
Khatib, I., Khanal, D., Ruan, J., Cipolla, D., Dayton, F., Blanchard, J. D., & Chan, H. K. (2019). Ciprofloxacin nanocrystals liposomal powders for controlled drug release via inhalation. International journal of pharmaceutics, 566, 641-651.
Khan, I., Elhissi, A., Shah, M., Alhnan, M., & Ahmed, W. (2013). Liposome-based carrier systems and devices used for pulmonary drug delivery. Biomaterials and Medical Tribology. 395–443. doi:10.1533/9780857092205.395
Kim, E., Erdos, G., Huang, S., Kenniston, T. W., Balmert, S. C., Carey, C. D., & Gambotto, A. (2020). Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development. EBioMedicine, 55, 102743.
Klinger-Strobel, M., Lautenschläger, C., Fischer, D., Mainz, J. G., Bruns, T., Tuchscherr, L., & Makarewicz, O. (2015). Aspects of pulmonary drug delivery strategies for infections in cystic fibrosis–where do we stand?. Expert opinion on drug delivery, 12(8), 1351-1374.
Kocks, J. W., Chrystyn, H., Van Der Palen, J., Thomas, M., Yates, L., Landis, S. H., & Molimard, M. (2018). Systematic review of association between critical errors in inhalation and health outcomes in asthma and COPD. NPJ primary care respiratory medicine, 28(1), 1-6.
Kumar, S., Ahlawat, W., Bhanjana, G., Heydarifard, S., Nazhad, M. M., & Dilbaghi, N. (2014). Nanotechnology-based water treatment strategies. Journal of nanoscience and nanotechnology, 14(2), 1838-1858.
Kumar, S., Gokhale, R., & Burgess, D. J. (2014). Sugars as bulking agents to prevent nano-crystal aggregation during spray or freeze-drying. International journal of pharmaceutics, 471(1-2), 303-311.
Labaki, W. W., & Rosenberg, S. R. (2020). Chronic Obstructive Pulmonary Disease. Annals of internal medicine, 173(3), ITC17–ITC32.
Labiris, N. R., & Dolovich, M. B. (2003). Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. British journal of clinical pharmacology, 56(6), 588-599.
Lam, G. Y., Desai, S., Fu, J., Hu, X. Y., Jang, J., Goshtasebi, A., & Quon, B. S. (2021). IL-8 correlates with reduced baseline femoral neck bone mineral density in adults with cystic fibrosis: a single center retrospective study. Scientific reports, 11(1), 1-8.
Lankveld, D. P., Oomen, A. G., Krystek, P., Neigh, A., Troost–de Jong, A., Noorlander, C. W., & De Jong, W. H. (2010). The kinetics of the tissue distribution of silver nanoparticles of different sizes. Biomaterials, 31(32), 8350-8361.
Larsson, K., Kankaanranta, H., Janson, C., Lehtimäki, L., Ställberg, B., Løkke, A., & Ulrik, C. S. (2020). Bringing asthma care into the twenty-first century. NPJ primary care respiratory medicine, 30(1), 1-11.
Lavelle, G. M., White, M. M., Browne, N., McElvaney, N. G., & Reeves, E. P. (2016). Animal models of cystic fibrosis pathology: phenotypic parallels and divergences. BioMed research international, 2016.
Lee, J., Huvanandana, J., Foster, J. M., Reddel, H. K., Abramson, M. J., Thamrin, C., & Hew, M. (2021). Dynamics of inhaled corticosteroid use are associated with asthma attacks. Scientific reports, 11(1), 1-12.
Lee, W. H., Loo, C. Y., Traini, D., & Young, P. M. (2015). Inhalation of nanoparticle-based drug for lung cancer treatment: Advantages and challenges. Asian journal of pharmaceutical sciences, 10(6), 481-489.
Lempp, F. A., Soriaga, L. B., Montiel-Ruiz, M., Benigni, F., Noack, J., Park, Y. J., & Corti, D. (2021). Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies. Nature, 598(7880), 342-347.
Leung, A. W., Amador, C., Wang, L. C., Mody, U. V., & Bally, M. B. (2019). What drives innovation: The canadian touch on liposomal therapeutics. Pharmaceutics, 11(3), 124.
Li, X., Vogt, F. G., Hayes Jr, D., & Mansour, H. M. (2014). Design, characterization, and aerosol dispersion performance modeling of advanced spray-dried microparticulate/nanoparticulate mannitol powders for targeted pulmonary delivery as dry powder inhalers. Journal of aerosol medicine and pulmonary drug delivery, 27(2), 81-93.
Lila, A. S. A., & Ishida, T. (2017). Liposomal delivery systems: design optimization and current applications. Biological and pharmaceutical bulletin, 40(1), 1-10.
Lima Salviano, T., dos Santos, M., Charles, D., de Siqueira Ferraz Carvalho, R., Pereira, M. A., de Arruda, B., & Cajubá de Britto Lira Nogueira, M. (2021). Fucoidan-Coated Liposomes: A Target System to Deliver the Antimicrobial Drug Usnic Acid to Macrophages Infected with Mycobacterium tuberculosis. Journal of Biomedical Nanotechnology, 17(8), 1699-1710.
Limsrivilai, J., & Pausawasdi, N. (2021). Intestinal tuberculosis or Crohn’s disease: a review of the diagnostic models designed to differentiate between these two gastrointestinal diseases. Intestinal research, 19(1), 21.
Loira-Pastoriza, C., Todoroff, J., & Vanbever, R. (2014). Delivery strategies for sustained drug release in the lungs. Advanced drug delivery reviews, 75, 81-91.
Long, K., & Suresh, K. (2020). Pulmonary toxicity of systemic lung cancer therapy. Respirology (Carlton, Vic.), 25 Suppl 2, 72–79.
López-Campos, J. L., Tan, W., & Soriano, J. B. (2016). Global burden of COPD. Respirology (Carlton, Vic.), 21(1), 14–23.
Macêdo, D. C. D. S. (2020). Avaliação de lipossomas sítio-específicos contendo ácido úsnico frente a macrófagos infectados com Mycobacterium tuberculosis (Master's thesis, Universidade Federal de Pernambuco).
Maiuri, L., Raia, V., & Kroemer, G. (2017). Strategies for the etiological therapy of cystic fibrosis. Cell Death & Differentiation, 24(11), 1825-1844.
Mannino, D. M., & Buist, A. S. (2007). Global burden of COPD: risk factors, prevalence, and future trends. The Lancet, 370(9589), 765-773.
Matera, M. G., Cazzola, M., & Page, C. (2021). Prospects for COPD treatment. Current Opinion in Pharmacology, 56, 74-84.
Matsunaga, K., Adachi, M., Nagase, H., Okoba, T., Hayashi, N., & Tohda, Y. (2020). Association of low-dosage systemic corticosteroid use with disease burden in asthma. NPJ primary care respiratory medicine, 30(1), 1-7.
Meers, P., Neville, M., Malinin, V., Scotto, A. W., Sardaryan, G., Kurumunda, R., & Perkins, W. R. (2008). Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. Journal of Antimicrobial Chemotherapy, 61(4), 859-868.
Meena, L. S. (2018). A novel approach in treatment of tuberculosis by targeting drugs to infected macrophages using biodegradable nanoparticles. Applied biochemistry and biotechnology, 185(3), 815-821.
Mishra, A. S., & Sugumaran, A. (2021). Nanoparticulate Delivery Systems for the Effective Treatment of COPD. Annals of the Romanian Society for Cell Biology, 13892-13904.
Misra, A., Jinturkar, K., Patel, D., Lalani, J., & Chougule, M. (2009). Recent advances in liposomal dry powder formulations: preparation and evaluation. Expert opinion on drug delivery, 6(1), 71-89.
Moll, M., Sakornsakolpat, P., Shrine, N., Hobbs, B. D., DeMeo, D. L., John, C., & International COPD Genetics Consortium. (2020). Chronic obstructive pulmonary disease and related phenotypes: polygenic risk scores in population-based and case-control cohorts. The Lancet Respiratory Medicine, 8(7), 696-708.
Muneswarao, J., Hassali, M. A., Ibrahim, B., Saini, B., Ali, I. A. H., & Verma, A. K. (2019). It is time to change the way we manage mild asthma: an update in GINA 2019. Respiratory research, 20(1), 1-6.
Muraglia, K. A., Chorghade, R. S., Kim, B. R., Tang, X. X., Shah, V. S., Grillo, A. S., & Burke, M. D. (2019). Small-molecule ion channels increase host defences in cystic fibrosis airway epithelia. Nature, 567(7748), 405-408.
Muralidharan, P., Malapit, M., Mallory, E., Hayes Jr, D., & Mansour, H. M. (2015). Inhalable nanoparticulate powders for respiratory delivery. Nanomedicine: Nanotechnology, Biology and Medicine, 11(5), 1189-1199.
Nguyen, T. X., Huang, L., Gauthier, M., Yang, G., & Wang, Q. (2016). Recent advances in liposome surface modification for oral drug delivery. Nanomedicine, 11(9), 1169-1185.
Nisini, R., Poerio, N., Mariotti, S., De Santis, F., & Fraziano, M. (2018). The multirole of liposomes in therapy and prevention of infectious diseases. Frontiers in Immunology, 9, 155.
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow CD, et al. (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ.;372:n71.
Passi, M., Shahid, S., Chockalingam, S., Sundar, I. K., & Packirisamy, G. (2020). Conventional and Nanotechnology Based Approaches to Combat Chronic Obstructive Pulmonary Disease: Implications for Chronic Airway Diseases. International journal of nanomedicine, 15, 3803–3826.
Patton, J. S. (1996). Mechanisms of macromolecule absorption by the lungs. Advanced drug delivery reviews, 19(1), 3-36.
Pham, D. D., Fattal, E., & Tsapis, N. (2015). Pulmonary drug delivery systems for tuberculosis treatment. International journal of pharmaceutics, 478(2), 517-529.
Poland, G. A. (2020). Another coronavirus, another epidemic, another warning. Vaccine, 38(10), v.
Priyadharshini, V. S., & Teran, L. M. (2016). Personalized medicine in respiratory disease: role of proteomics. Advances in Protein Chemistry and Structural Biology, 102, 115-146.
Purohit, D., Manchanda, D., Makhija, M., Rathi, J., Verma, R., Kaushik, D., & Pandey, P. (2021). An Overview of the Recent Developments and Patents in the Field of Pharmaceutical Nanotechnology. Recent Patents on Nanotechnology, 15(1), 15-34.
Qiu, Y., Zhao, Y. B., Wang, Q., Li, J. Y., Zhou, Z. J., Liao, C. H., & Ge, X. Y. (2020). Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2. Microbes and infection, 22(4-5), 221-225.
Quoc, Q. L., Choi, Y., Thi Bich, T. C., Yang, E. M., Shin, Y. S., & Park, H. S. (2021). S100A9 in adult asthmatic patients: a biomarker for neutrophilic asthma. Experimental & Molecular Medicine, 53(7), 1170-1179.
Olawoye, I. B., Uwanibe, J. N., Kunle-Ope, C. N., Davies-Bolorunduro, O. F., Abiodun, T. A., Audu, R. A., & Happi, C. T. (2021). Whole genome sequencing of clinical samples reveals extensively drug resistant tuberculosis (XDR TB) strains from the Beijing lineage in Nigeria, West Africa. Scientific reports, 11(1), 1-8.
Osamor, V. C., & Okezie, A. F. (2021). Enhancing the weighted voting ensemble algorithm for tuberculosis predictive diagnosis. Scientific Reports, 11(1), 1-11.
Öztürk, A. A., Namlı, İ., Güleç, K., & Görgülü, Ş. (2020). Design of lamivudine loaded nanoparticles for oral application by nano spray drying method: a new approach to use an antiretroviral drug for lung cancer treatment. Combinatorial Chemistry & High Throughput Screening, 23(10), 1064-1079.
Ran, Q., Xiang, Y., Liu, Y., Xiang, L., Li, F., Deng, X., & Li, Z. (2015). Eryptosis indices as a novel predictive parameter for biocompatibility of Fe3O4 magnetic nanoparticles on erythrocytes. Scientific reports, 5(1), 1-15.
Savla & Tamara (2013). Nanotechnology approaches for inhalation treatment of fibrosis, Journal of Drug Targeting, 21:10, 914-925
Schabath, M. B., & Cote, M. L. (2019). Cancer progress and priorities: lung cancer. Cancer epidemiology, biomarkers & prevention, 28(10), 1563-1579.
Schneider-Futschik, E. K. (2019). Beyond cystic fibrosis transmembrane conductance regulator therapy: a perspective on gene therapy and small molecule treatment for cystic fibrosis. Gene therapy, 26(9), 354-362.
Seimetz, M., Sommer, N., Bednorz, M., Pak, O., Veith, C., Hadzic, S., & Weissmann, N. (2020). NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD. Nature Metabolism, 2(6), 532-546.
Semilan, H. M., Abugad, H. A., Mashat, H. M., & Abdel Wahab, M. M. (2021). Epidemiology of tuberculosis among different occupational groups in Makkah region, Saudi Arabia. Scientific Reports, 11(1), 1-8.
Shafiei-Jahani, P., Helou, D. G., Hurrell, B. P., Howard, E., Quach, C., Painter, J. D., & Akbari, O. (2021). CD200–CD200R immune checkpoint engagement regulates ILC2 effector function and ameliorates lung inflammation in asthma. Nature Communications, 12(1), 1-15.
Shakshuki, A., & Agu, R. U. (2017). Improving the efficiency of respiratory drug delivery: a review of current treatment trends and future strategies for asthma and chronic obstructive pulmonary disease. Pulmonary Therapy, 3(2), 267-281.
Sharma, S., Javed, M. N., Pottoo, F. H., Rabbani, S. A., Barkat, M., Sarafroz, M., & Amir, M. (2019). Bioresponse inspired nanomaterials for targeted drug and gene delivery. Pharmaceutical nanotechnology, 7(3), 220-233.
Shaw, J. A., & Koegelenberg, C. F. (2021). Pleural tuberculosis. Clinics in Chest Medicine, 42(4), 649-666.
Shereen, M. A., Khan, S., Kazmi, A., Bashir, N., & Siddique, R. (2020). COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses. Journal of advanced research, 24, 91-98.
Shetty, N., Cipolla, D., Park, H., & Zhou, Q. T. (2020). Physical stability of dry powder inhaler formulations. Expert opinion on drug delivery, 17(1), 77–96.
Silva, A. L (2019). Nanotecnologia aplicada à dermocosméticos. Trabalho de Conclusão de Curso (Graduação em Farmácia) - Centro Universitário da Zona Oeste, 2019.
Silva, A. L., de Oliveira, G. P., Kim, N., Cruz, F. F., Kitoko, J. Z., Blanco, N. G., & Morales, M. M. (2020). Nanoparticle-based thymulin gene therapy therapeutically reverses key pathology of experimental allergic asthma. Science advances, 6(24), eaay7973.
Society, A. C. (2018). Global cancer facts and figures (4th edition). Am Cancer Soc, 1, 1-73.
Souza, M. T. D., Silva, M. D. D., & Carvalho, R. D. (2010). Revisão integrativa: o que é e como fazer. Einstein (São Paulo), 8, 102-106.
Suer, H., & Bayram, H. (2017). Liposomes as potential nanocarriers for theranostic applications in chronic inflammatory lung diseases. Biomedical and Biotechnology Research Journal (BBRJ), 1(1), 1.
Sia, J. K., & Rengarajan, J. (2019). Immunology of Mycobacterium tuberculosis infections. Microbiology spectrum, 7(4), 7-4.
Siegel, R. L., Miller, K. D., & Jemal, A. (2019). Cancer statistics, 2019. CA: a cancer journal for clinicians, 69(1), 7-34.
Sigel, K., Wisnivesky, J., Gordon, K., Dubrow, R., Justice, A., Brown, S. T., & Crothers, K. (2012). HIV as an independent risk factor for incident lung cancer. AIDS (London, England), 26(8), 1017.
Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019). Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles. Signal transduction and targeted therapy, 4(1), 1-21.
Su, Q. D., Yi, Y., Zou, Y. N., Jia, Z. Y., Qiu, F., Wang, F., & Wu, G. Z. (2020). The biological characteristics of SARS-CoV-2 spike protein Pro330-Leu650. Vaccine, 38(32), 5071-5075.
Sweeney, L. G., Wang, Z., Loebenberg, R., Wong, J. P., Lange, C. F., & Finlay, W. H. (2005). Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery. International journal of pharmaceutics, 305(1-2), 180-185.
Tavares, J. L., Cavalcanti, I. D. L., Santos Magalhães, N. S., & Lira Nogueira, M. C. D. B. (2022). Nanotechnology and COVID-19: quo vadis?. Journal of Nanoparticle Research, 24(3), 1-22.
The Global Asthma Report 2018 (2018). Auckland, New Zealand: Global Asthma Network.
Thiyagarajan, D., Huck, B., Nothdurft, B., Koch, M., Rudolph, D., Rutschmann, M., & Lehr, C. M. (2021). Spray-dried lactose-leucine microparticles for pulmonary delivery of antimycobacterial nanopharmaceuticals. Drug delivery and translational research, 11(4), 1766-1778.
Tiberi, S., du Plessis, N., Walzl, G., Vjecha, M. J., Rao, M., Ntoumi, F., & Zumla, A. (2018). Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. The Lancet Infectious Diseases, 18(7), e183-e198.
Torchilin, V. P. (2010). Passive and active drug targeting: drug delivery to tumors as an example. Drug delivery, 3-53.
Trandafir, L. M., Leon, M. M., Frasinariu, O., Baciu, G., Dodi, G., & Cojocaru, E. (2019). Current practices and potential nanotechnology perspectives for pain related to cystic fibrosis. Journal of Clinical Medicine, 8(7), 1023.
Rabe, K. F., & Watz, H. (2017). Chronic obstructive pulmonary disease. Lancet (London, England), 389(10082), 1931–1940.
Rezaei, N., Mehrnejad, F., Vaezi, Z., Sedghi, M., Asghari, S. M., & Naderi-Manesh, H. (2020). Encapsulation of an endostatin peptide in liposomes: Stability, release, and cytotoxicity study. Colloids and Surfaces B: Biointerfaces, 185, 110552.
Roche, N. (2018). Stable COPD treatment: where are we?. COPD: Journal of Chronic Obstructive Pulmonary Disease, 15(2), 123-129.
Rossi-Bergmann, B. (2008). A nanotecnologia: da saúde para além do determinismo tecnológico. Ciência e Cultura, 60(2), 54-57.
Ungaro, F., d'Angelo, I., Coletta, C., di Villa Bianca, R. D. E., Sorrentino, R., Perfetto, B., & Quaglia, F. (2012). Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. Journal of controlled release, 157(1), 149-159.
van den Hoven, J. M., Metselaar, J. M., Storm, G., Beijnen, J. H., & Nuijen, B. (2012). Cyclodextrin as membrane protectant in spray-drying and freeze-drying of PEGylated liposomes. International journal of pharmaceutics, 438(1-2), 209-216.
Velavan, T. P., & Meyer, C. G. (2020). The COVID‐19 epidemic. Tropical medicine & international health, 25(3), 278.
Viniol, C., & Vogelmeier, C. F. (2018). Exacerbations of COPD. European Respiratory Review, 27(147).
Vogelmeier, C. F., Román-Rodríguez, M., Singh, D., Han, M. K., Rodríguez-Roisin, R., & Ferguson, G. T. (2020). Goals of COPD treatment: Focus on symptoms and exacerbations. Respiratory medicine, 166, 105938.
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., & Bell, M. L. (2016). Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. The lancet, 388(10053), 1459-1544.
Wang, Y., Wrennall, J. A., Cai, Z., Li, H., & Sheppard, D. N. (2014). Understanding how cystic fibrosis mutations disrupt CFTR function: from single molecules to animal models. The international journal of biochemistry & cell biology, 52, 47–57.
Wolff, R. K. (1998). Safety of inhaled proteins for therapeutic use. Journal of aerosol medicine: the official journal of the International Society for Aerosols in Medicine, 11(4), 197–219.
World Health Organization [WHO] (2019). Global Tuberculosis Report. Geneva: World Health Organization.
World Health Organization [WHO] (2020). Global Tuberculosis Report 2020. Geneva: World Health Organization.
World Health Organization [WHO] (2020). Estimating Mortality From Covid-19.
World Health Organization [WHO] (2020). Global Surveillance For Human Infection With Coronavirus Disease (Covid-19).
World Health Organization (2022). Chronic obstructive pulmonary disease (COPD). Genebra: WHO. https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd).
Wu, C., Liu, Y., Yang, Y., Zhang, P., Zhong, W., Wang, Y., & Li, H. (2020). Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B, 10(5), 766-788.
Xu, J., Lu, X., Zhu, X., Yang, Y., Liu, Q., Zhao, D., & Li, N. (2019). Formulation and characterization of spray-dried powders containing vincristine-liposomes for pulmonary delivery and its pharmacokinetic evaluation from in vitro and in vivo. Journal of Pharmaceutical Sciences, 108(10), 3348-3358.
Yang, S., Cao, P., Du, P., Wu, Z., Zhuang, Z., Yang, L., & He, D. (2020). Early estimation of the case fatality rate of COVID-19 in mainland China: a data-driven analysis. Annals of translational medicine, 8(4).
Ye, T., Yu, J., Luo, Q., Wang, S., & Chan, H. K. (2017). Inhalable clarithromycin liposomal dry powders using ultrasonic spray freeze drying. Powder Technology, 305, 63-70.
Yu, T., Chan, K. W., Anonuevo, A., Song, X., Schuster, B. S., Chattopadhyay, S., & Hanes, J. (2015). Liposome-based mucus-penetrating particles (MPP) for mucosal theranostics: demonstration of diamagnetic chemical exchange saturation transfer (diaCEST) magnetic resonance imaging (MRI). Nanomedicine: Nanotechnology, Biology and Medicine, 11(2), 401-405.
Zhang, J., Wu, L., Chan, H. K., & Watanabe, W. (2011). Formation, characterization, and fate of inhaled drug nanoparticles. Advanced drug delivery reviews, 63(6), 441-455.
Zhang, T., Chen, Y., Ge, Y., Hu, Y., Li, M., & Jin, Y. (2018). Inhalation treatment of primary lung cancer using liposomal curcumin dry powder inhalers. Acta pharmaceutica Sinica. B, 8(3), 440–448.
Zylberberg, C., & Matosevic, S. (2016). Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape. Drug delivery, 23(9), 3319-3329.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Karlle Tathyana de Almeida Santos; Daniel Charles dos Santos Macedo; Luana Bastos da Silva; Mariane Cajubá de Britto Lira Nogueira
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
